1733 — Apex Biotechnology Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Apex Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,199	2,005	2,132	2,244	1,677
Cost of Revenue
Gross Profit	591	452	572	577	531
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	2,003	1,902	1,927	2,093	1,553
Operating Profit	196	103	205	152	124
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	163	111	185	200	141
Provision for Income Taxes
Net Income After Taxes	113	94.6	202	181	116
Minority Interest
Net Income Before Extraordinary Items
Net Income	114	94.8	202	182	116
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	118	98.7	204	182	116
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.09	0.873	1.93	2.03	1.3
Dividends per Share